We substantiated the results of the in vitro-treatment of primary patient cells with three additional patient leukemia cells, patient #805 (DNTM3A- and FLT3-ITD-mutant), patient #770 (only DNMT3A-mutant) and #719 (FLT3-ITD) (Additional file 1: Figure S3). This evidence concerns the gene DNMT3A and leukemia.